speb/financial-data huggingface dataset:
Financial ratios for VYS.AX — annual report dated 2023-06-30
Total revenue: 43017984.105960265
Gross profit: 14318415.894039735
Operating income: 4933062.913907285
Net income: 2564607.9470198676
Capital expenditures: 2652352.9801324503
Depreciation & amortization: 3228776.158940397
Net tangible assets: 20208166.225165565
Owner earnings: 3141031.1258278145
Return on net tangible assets (%): 15.543375340589966
Capex to operating income (%): 53.76685897629524
Buffett classification: The Good
Stock price: 0.09933774834437085
P/E ratio: 20.430094100591905
Shares outstanding: 527444829
Book value: 21803751.65562914
P/B ratio: 2.403035152678172
Market cap (USD): 52395181.68874172
Debt to equity: 0.30478985252705004
Current ratio: 1.9721693992915492
Quick ratio: 1.6937484988108176
Effective tax rate (%): 45.26860733481543
Interest coverage ratio: 14.425641065366301
COGS to revenue (%): 66.71527922189205
SG&A to revenue (%): 14.311636426939629
Free cash flow (dilution-adjusted): 3674867.549668874
Buyback yield (%): 0
Retained earnings: 8126556.291390728
Inventory turnover: 10.120663704320936
Receivables turnover: 6.248412193171349
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 16.66429156920191
FCF margin (%): 8.542630776507517
Revenue growth (%): 34.729096817308466
Rule of 40 score: 43.27172759381598
Financial ratios for ZENSARTECH.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.452723196624027
Shares outstanding: 226752635
Market cap (USD): 1009666717.7601212
Buyback yield (%): 0
Retained earnings: 186891731.50468153
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZENSARTECH.NS — annual report dated 2023-03-31
Total revenue: 590523751.5225335
Gross profit: 132496954.93300854
Operating income: 45127892.813641906
Net income: 39902557.85627284
Capital expenditures: 4068209.5006090137
Operating cash flow: 87003654.08038977
Depreciation & amortization: 22289890.37758831
Net tangible assets: 259305724.72594398
Owner earnings: 58124238.73325214
Return on net tangible assets (%): 22.41533186152473
Capex to operating income (%): 9.014844804318487
Buffett classification: The Great
Stock price: 3.1373934226552986
P/E ratio: 17.828737400274726
Shares outstanding: 226752635
Book value: 362509135.20097446
P/B ratio: 1.9624670292083866
Market cap (USD): 711412225.6187576
Debt to equity: 0.09172770647133928
Current ratio: 2.701468189233279
Quick ratio: 2.701468189233279
Effective tax rate (%): 26.232830443593784
Interest coverage ratio: 14.305019305019306
COGS to revenue (%): 77.56280681490037
SG&A to revenue (%): 2.308073099294584
Free cash flow (dilution-adjusted): 80779537.1498173
Buyback yield (%): 0
Retained earnings: 203325213.15468943
Receivables turnover: 6.641369863013699
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.355277675616037
FCF margin (%): 13.679303659089973
Rule of 40 score: 13.679303659089973
Financial ratios for ZENSARTECH.NS — annual report dated 2024-03-31
Total revenue: 587828276.7717952
Gross profit: 168437462.52548268
Operating income: 90010792.66099052
Net income: 79745772.87444538
Capital expenditures: 1810768.6772994364
Operating cash flow: 76999640.24463364
Depreciation & amortization: 16045089.339249311
Net tangible assets: 329967622.0170284
Owner earnings: 93980093.53639525
Return on net tangible assets (%): 28.48161069922954
Capex to operating income (%): 2.0117239541699976
Buffett classification: The Great
Stock price: 6.9103886756238
P/E ratio: 19.649302835636412
Shares outstanding: 226752635
Book value: 427137546.4684015
P/B ratio: 3.668487713214356
Market cap (USD): 1566948841.071857
Debt to equity: 0.05235969566804234
Current ratio: 3.0375878220140513
Quick ratio: 3.0375878220140513
Effective tax rate (%): 24.069422242521128
Interest coverage ratio: 39.29842931937173
COGS to revenue (%): 71.34580468797813
SG&A to revenue (%): 2.166506864685122
Free cash flow (dilution-adjusted): 72226885.71771196
Buyback yield (%): 0
Retained earnings: 264408202.4223528
Receivables turnover: 6.696584699453552
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 19.784912225209553
FCF margin (%): 12.28707235969726
Revenue growth (%): -0.4564549256128484
Rule of 40 score: 11.830617434084413
Financial ratios for ZENSARTECH.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 325824175.82417583
Buffett classification: The Gruesome
Stock price: 7.72706641184902
Shares outstanding: 226752635
Book value: 442642140.4682275
P/B ratio: 3.9583503456163305
Market cap (USD): 1752132669.7067606
Debt to equity: 0.03964056344109234
Current ratio: 3.2935181893589287
Quick ratio: 3.2935181893589287
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZENSARTECH.NS — quarterly report dated 2024-12-31
Total revenue: 154516843.45494813
Gross profit: 35295488.984730154
Operating income: 21366126.588180438
Net income: 18626879.589695767
Capital expenditures: 0
Depreciation & amortization: 2762559.7388973073
Owner earnings: 21389439.328593075
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 8.392586548548781
P/E ratio: 25.54159843554443
Shares outstanding: 226752635
Market cap (USD): 1903041114.3489916
Effective tax rate (%): 24.01331431288635
Interest coverage ratio: 49.54054054054054
COGS to revenue (%): 77.15751357875678
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZENSARTECH.NS — quarterly report dated 2025-03-31
Total revenue: 158861351.41454288
Gross profit: 34685527.238718726
Operating income: 22059855.03857844
Net income: 20621931.26022913
Capital expenditures: 0
Depreciation & amortization: 2782324.0589198032
Net tangible assets: 360977320.5517886
Owner earnings: 23404255.31914893
Return on net tangible assets (%): 6.483580542781267
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 7.853775236316957
P/E ratio: 21.58944532231011
Shares outstanding: 226752635
Book value: 475765723.6380641
P/B ratio: 3.7431537016050345
Market cap (USD): 1780864229.5326176
Debt to equity: 0.030763938373835904
Current ratio: 3.757197914305146
Quick ratio: 3.757197914305146
Effective tax rate (%): 23.237597911227155
Interest coverage ratio: 38.510204081632644
COGS to revenue (%): 78.16616380896313
Buyback yield (%): 0
Retained earnings: 314519523.0301613
Receivables turnover: 1.719908872294646
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.397883795184934
Revenue growth (%): 2.8116727357697204
Rule of 40 score: 2.8116727357697204
Financial ratios for ZENSARTECH.NS — annual report dated 2025-03-31
Total revenue: 617325227.9635258
Gross profit: 167792845.4524199
Operating income: 85422024.7837269
Net income: 75964461.07084404
Capital expenditures: 4126724.339490297
Operating cash flow: 66050970.30628945
Depreciation & amortization: 11912555.529576804
Net tangible assets: 360977320.5517886
Owner earnings: 83750292.26093055
Return on net tangible assets (%): 23.200984519722777
Capex to operating income (%): 4.830983987956754
Buffett classification: The Great
Stock price: 7.853775236316957
P/E ratio: 23.443386610375523
Shares outstanding: 226752635
Book value: 475765723.6380641
P/B ratio: 3.7431537016050345
Market cap (USD): 1780864229.5326176
Debt to equity: 0.030763938373835904
Current ratio: 3.757197914305146
Quick ratio: 3.757197914305146
Effective tax rate (%): 24.239244491080797
Interest coverage ratio: 47.14193548387097
COGS to revenue (%): 72.81937658599402
SG&A to revenue (%): 2.1209711017687387
Free cash flow (dilution-adjusted): 58043020.80897825
Buyback yield (%): 0
Retained earnings: 314519523.0301613
Receivables turnover: 6.6834577901531445
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.029855268371126
FCF margin (%): 9.402340643108738
Revenue growth (%): 5.017953772778752
Rule of 40 score: 14.42029441588749
Financial ratios for ZENSARTECH.NS — quarterly report dated 2025-06-30
Total revenue: 162064123.56658086
Gross profit: 36941259.06857009
Operating income: 21940088.930493798
Net income: 21296512.988532647
Capital expenditures: 0
Depreciation & amortization: 2703018.956236836
Owner earnings: 23999531.944769483
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 9.467002106248538
P/E ratio: 35.45554862122766
Shares outstanding: 226752635
Market cap (USD): 2146667673.142406
Effective tax rate (%): 24.355777223607646
Interest coverage ratio: 52.08333333333333
COGS to revenue (%): 77.2057761732852
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 2.0160801375033386
Rule of 40 score: 2.0160801375033386
Financial ratios for ZENSARTECH.NS — quarterly report dated 2025-12-31
Total revenue: 159373955.6644759
Gross profit: 38030522.446251534
Operating income: 25576473.20931269
Net income: 22256878.68998552
Capital expenditures: 0
Depreciation & amortization: 2261334.521555085
Owner earnings: 24518213.211540606
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 7.62582154394564
P/E ratio: 20.88320209278805
Shares outstanding: 226752635
Market cap (USD): 1729175129.1294422
Effective tax rate (%): 24.60377358490566
Interest coverage ratio: 99.82608695652173
COGS to revenue (%): 76.13755504298597
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -1.6599404253710544
Rule of 40 score: -1.6599404253710544
Financial ratios for ZSTK — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1388.4
Shares outstanding: 2430808
Market cap (USD): 3374933827.2000003
Buyback yield (%): 0
Capitalized R&D asset: 103937.00787401575
Rule of 40 score: 0
Financial ratios for ZSTK — annual report dated 2022-12-31
Total revenue: 24559558.82352941
Gross profit: 9743382.352941176
Operating income: -15072794.117647057
Net income: -38540441.176470585
Capital expenditures: 951470.5882352941
Operating cash flow: -11716911.764705881
Depreciation & amortization: 1933088.2352941176
Net tangible assets: 11552941.176470587
Owner earnings: -37558823.52941176
Return on net tangible assets (%): -325.10183299389
Buffett classification: The Gruesome
Stock price: 177.84
Shares outstanding: 2430808
Book value: 41479411.76470588
P/B ratio: 10.421914784428846
Market cap (USD): 432294894.72
Debt to equity: 0.06670566546124937
Current ratio: 1.7856938155556827
Quick ratio: 1.2843468791196193
COGS to revenue (%): 60.32753510373941
R&D to revenue (%): 1.1616418670099695
SG&A to revenue (%): 86.15610311068531
Free cash flow (dilution-adjusted): -15171323.529411763
Buyback yield (%): 0.043373170095252885
Retained earnings: -66812499.99999999
Inventory turnover: 2.3036469646736024
Receivables turnover: 3.728206273021543
Capitalized R&D asset: 354931.91292264935
ROCI (R&D-adjusted, %): -31.687899913883573
FCF margin (%): -61.77359959282656
Rule of 40 score: -61.77359959282656
Financial ratios for ZSTK — annual report dated 2023-12-31
Total revenue: 57629545.45454545
Gross profit: 13437878.787878787
Operating income: -8038636.363636363
Net income: -42687121.21212121
Capital expenditures: 123484.84848484848
Operating cash flow: -6360606.060606061
Depreciation & amortization: 1881818.1818181816
Net tangible assets: 4134848.484848485
Owner earnings: -40928787.87878788
Return on net tangible assets (%): -989.8497618175156
Buffett classification: The Gruesome
Stock price: 52.65
Shares outstanding: 2430808
Book value: 4851515.15151515
P/B ratio: 26.37980861711431
Market cap (USD): 127982041.2
Debt to equity: 0.5733916302311056
Current ratio: 1.3122850122850125
Quick ratio: 0.7896805896805897
Interest coverage ratio: -115.33695652173913
COGS to revenue (%): 76.68230994728609
R&D to revenue (%): 0.08150280658858172
SG&A to revenue (%): 30.675290189428296
Free cash flow (dilution-adjusted): -7689393.939393939
Buyback yield (%): 0
Retained earnings: -107991666.66666666
Inventory turnover: 6.856252938410908
Receivables turnover: 10.709700126707027
Capitalized R&D asset: 272415.9683916516
ROCI (R&D-adjusted, %): -139.39139827967156
Rosenberg metric: 12.94978131833802
FCF margin (%): -13.342798175388781
Revenue growth (%): 134.65220148552984
Rule of 40 score: 121.30940331014106
Financial ratios for ZSTK — quarterly report dated 2024-09-30
Capital expenditures: 14814.814814814814
Buffett classification: The Gruesome
Stock price: 59.67
Shares outstanding: 2430808
Market cap (USD): 145046313.36
Buyback yield (%): 0
Capitalized R&D asset: 87407.4074074074
Rule of 40 score: 0
Financial ratios for ZSTK — quarterly report dated 2024-12-31
Capital expenditures: 0
Depreciation & amortization: 147552.44755244756
Buffett classification: The Gruesome
Stock price: 40.17
Shares outstanding: 2430808
Market cap (USD): 97645557.36
Buyback yield (%): 0
Capitalized R&D asset: 192129.39652939653
Rule of 40 score: 0
Financial ratios for ZSTK — annual report dated 2024-12-31
Total revenue: 25080419.58041958
Gross profit: 1535664.3356643356
Operating income: -6218881.118881119
Net income: -11123776.223776225
Capital expenditures: 93706.29370629371
Operating cash flow: -3518881.118881119
Depreciation & amortization: 537062.9370629371
Net tangible assets: 3153846.153846154
Owner earnings: -10680419.580419581
Return on net tangible assets (%): -338.6474501108648
Buffett classification: The Gruesome
Stock price: 40.17
Shares outstanding: 2430808
Book value: 3153846.153846156
P/B ratio: 30.96078647999998
Market cap (USD): 97645557.36
Debt to equity: 0.517073170731707
Current ratio: 1.0494371282922685
Quick ratio: 0.9305437553101105
Interest coverage ratio: -63.97841726618705
COGS to revenue (%): 93.87703889585947
R&D to revenue (%): 1.165481667363725
SG&A to revenue (%): 30.81834657744319
Free cash flow (dilution-adjusted): -5555944.055944056
Buyback yield (%): 0
Retained earnings: -110587412.5874126
Inventory turnover: 15.037516748548459
Receivables turnover: 6.175103305785124
Capitalized R&D asset: 417924.4481009187
ROCI (R&D-adjusted, %): -109.75999472193622
Rosenberg metric: -253.40198511166253
FCF margin (%): -22.152516380872715
Revenue growth (%): -56.479928164275684
Rule of 40 score: -78.6324445451484
Financial ratios for ZSTK — quarterly report dated 2025-03-31
Total revenue: 4801398.601398601
Gross profit: 374125.87412587414
Operating income: -1100000
Net income: -530069.93006993
Capital expenditures: 16783.216783216783
Operating cash flow: -1860839.160839161
Depreciation & amortization: 127272.72727272728
Net tangible assets: -1714685.3146853147
Owner earnings: -419580.41958041955
Buffett classification: The Gruesome
Stock price: 23.59
Shares outstanding: 2430808
Book value: 3327272.7272727266
P/B ratio: 17.234163057923503
Market cap (USD): 57342760.72
Debt to equity: 1.534678436317781
Current ratio: 1.049801429706116
Quick ratio: 0.6691818903891977
Interest coverage ratio: -68.39130434782608
COGS to revenue (%): 92.20798135741335
R&D to revenue (%): 1.6457908534809205
SG&A to revenue (%): 20.550538887270612
Free cash flow (dilution-adjusted): -1997902.097902098
Buyback yield (%): 0
Retained earnings: -111117482.51748252
Inventory turnover: 1.3211602671118532
Receivables turnover: 1.6957273400839712
Capitalized R&D asset: 197354.93395493395
ROCI (R&D-adjusted, %): -15.89137462373203
FCF margin (%): -41.610836003495486
Rule of 40 score: -41.610836003495486
Financial ratios for ZSTK — quarterly report dated 2025-06-30
Total revenue: 10800000
Gross profit: 2065693.4306569342
Operating income: -1683941.605839416
Net income: -1760583.9416058392
Capital expenditures: 47445.25547445255
Operating cash flow: -2156934.306569343
Depreciation & amortization: 142335.76642335765
Net tangible assets: -2476642.335766423
Owner earnings: -1665693.4306569342
Buffett classification: The Gruesome
Stock price: 22.62
Shares outstanding: 2430808
Book value: 2936496.3503649626
P/B ratio: 18.724653600596575
Market cap (USD): 54984876.96
Debt to equity: 1.93238876460353
Current ratio: 0.9557502896871379
Quick ratio: 0.608053302433372
COGS to revenue (%): 80.87320897539875
R&D to revenue (%): 0.4933765882670992
SG&A to revenue (%): 33.44147066774804
Free cash flow (dilution-adjusted): -2329927.00729927
Buyback yield (%): 0
Retained earnings: -117744525.54744525
Inventory turnover: 2.4923974172047494
Receivables turnover: 2.9080188679245285
Capitalized R&D asset: 150305.65055382575
ROCI (R&D-adjusted, %): -25.983850331656132
Rosenberg metric: 21.406562883534654
FCF margin (%): -21.57339821573398
Revenue growth (%): 124.93445965627731
Rule of 40 score: 103.36106144054332
Financial ratios for ZSTK — quarterly report dated 2025-09-30
Total revenue: 7012949.64028777
Gross profit: 241007.19424460432
Operating income: -2356834.5323741008
Net income: -4790647.482014389
Capital expenditures: 6474.820143884893
Operating cash flow: 71942.44604316547
Depreciation & amortization: 144604.3165467626
Net tangible assets: 46705035.97122303
Owner earnings: -4652517.985611511
Return on net tangible assets (%): -9.961491065927296
Buffett classification: The Gruesome
Stock price: 17.27
Shares outstanding: 2430808
Book value: 46705035.97122302
P/B ratio: 0.898833568736907
Market cap (USD): 41980054.16
Debt to equity: 0.049984596426370924
Current ratio: 2.080027595722663
Quick ratio: 1.7945268483385075
Interest coverage ratio: -53.70491803278688
COGS to revenue (%): 96.56339762002463
SG&A to revenue (%): 28.077554370127206
Free cash flow (dilution-adjusted): -323741.0071942446
Buyback yield (%): 0
Retained earnings: -120780575.53956835
Inventory turnover: 3.7909786548530007
Receivables turnover: 4.2530541012216405
Capitalized R&D asset: 61777.653003930376
ROCI (R&D-adjusted, %): -5.102527640900119
Rosenberg metric: -34.24411156006701
FCF margin (%): -4.616331555190808
Revenue growth (%): -35.06528110844657
Rule of 40 score: -39.68161266363738
Financial ratios for ZSTK — quarterly report dated 2025-12-31
Total revenue: 6827007.299270072
Gross profit: 116788.3211678832
Operating income: -3504379.5620437954
Net income: -80221167.88321167
Capital expenditures: 21167.88321167883
Operating cash flow: -2306569.343065693
Depreciation & amortization: 2919.70802919708
Net tangible assets: -1020437.9562043794
Owner earnings: -80239416.05839415
Buffett classification: The Gruesome
Stock price: 6.26
Shares outstanding: 2430808
Book value: 51497810.21897809
P/B ratio: 0.29548553647805875
Market cap (USD): 15216858.08
Debt to equity: 0.7644148996484863
Current ratio: 1.0101993509503941
Quick ratio: 0.7903337969401948
Interest coverage ratio: -137.17142857142858
COGS to revenue (%): 98.28931893510105
SG&A to revenue (%): 44.12487971773763
Free cash flow (dilution-adjusted): -2563503.649635036
Buyback yield (%): 0
Retained earnings: -202764963.50364962
Inventory turnover: 4.84607274644175
Receivables turnover: 11.705882352941176
Capitalized R&D asset: 17583.941605839416
ROCI (R&D-adjusted, %): -3.9671874463456125
FCF margin (%): -37.54944937453224
Revenue growth (%): -2.6514141774169073
Rule of 40 score: -40.20086355194915
Financial ratios for ZSTK — annual report dated 2025-12-31
Total revenue: 26040875.912408758
Gross profit: 1203649.6350364962
Operating income: -8237956.204379561
Net income: -87395620.4379562
Capital expenditures: 92700.7299270073
Operating cash flow: -6332846.715328467
Depreciation & amortization: 424817.51824817515
Net tangible assets: -1020437.9562043794
Owner earnings: -87063503.64963503
Buffett classification: The Gruesome
Stock price: 6.26
Shares outstanding: 2430808
Book value: 51497810.21897809
P/B ratio: 0.29548553647805875
Market cap (USD): 15216858.08
Debt to equity: 0.7644148996484863
Current ratio: 1.0101993509503941
Quick ratio: 0.7903337969401948
Interest coverage ratio: -56.713567839195974
COGS to revenue (%): 95.37784504989347
SG&A to revenue (%): 29.68662406099338
Free cash flow (dilution-adjusted): -7307299.270072992
Buyback yield (%): 0
Retained earnings: -202764963.50364962
Inventory turnover: 17.937269372693724
Receivables turnover: 44.65081351689612
Capitalized R&D asset: 211346.15384615387
ROCI (R&D-adjusted, %): -9.385776066610381
Rosenberg metric: -1.1358397653057664
FCF margin (%): -28.060881264715775
Revenue growth (%): 3.829506635283765
Rule of 40 score: -24.23137462943201
Financial ratios for BAJAJINDEF.NS — annual report dated 2023-03-31
Capital expenditures: 0
Operating cash flow: -828.258221680877
Net tangible assets: 60.90133982947625
Buffett classification: The Gruesome
Shares outstanding: 32000000
Book value: 60.90133982947623
Debt to equity: 0
Current ratio: 1.2307692307692308
Quick ratio: 1.2307692307692308
Free cash flow (dilution-adjusted): -828.258221680877
Retained earnings: -1157.1254567600488
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BAJAJINDEF.NS — annual report dated 2024-03-31
Total revenue: 0
Operating income: -7159.13179038254
Net income: -5240.436503177839
Capital expenditures: 0
Operating cash flow: -7063.197026022305
Net tangible assets: -5180.477275452692
Owner earnings: -5240.436503177839
Buffett classification: The Gruesome
Shares outstanding: 32000000
Book value: -5180.477275452691
Debt to equity: -1.6342592592592593
Current ratio: 0.1960526315789474
Quick ratio: 0.1960526315789474
Interest coverage ratio: -33.16666666666667
Free cash flow (dilution-adjusted): -7063.197026022305
Retained earnings: -6379.66182995563
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BAJAJINDEF.NS — annual report dated 2025-03-31
Total revenue: 20747463.17512275
Gross profit: 8481377.133504793
Operating income: 2993371.5220949263
Net income: 3993488.4264671495
Capital expenditures: 1016249.7077390694
Operating cash flow: 562988.0757540332
Depreciation & amortization: 605833.5281739536
Net tangible assets: 29005202.244563945
Owner earnings: 3583072.2469020337
Return on net tangible assets (%): 12.353205527375906
Capex to operating income (%): 33.950002538536936
Buffett classification: The Good
Shares outstanding: 32000000
Book value: 29565489.829319615
Debt to equity: 0.0153121826849166
Current ratio: 1.9325214157241717
Quick ratio: 1.256403377739841
Effective tax rate (%): 18.569981287469755
Interest coverage ratio: 60.233592095977414
COGS to revenue (%): 59.12089559134925
SG&A to revenue (%): 4.6197804971776115
Free cash flow (dilution-adjusted): -465571.662380173
Retained earnings: 9280722.46902034
Inventory turnover: 4.730849869469356
Receivables turnover: 5.54273061163302
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.532916751675733
FCF margin (%): -2.2439931978692065
Rule of 40 score: -2.2439931978692065
Financial ratios for BAJAJINDEF.NS — quarterly report dated 2025-03-31
Total revenue: 6193277.998597147
Gross profit: 3022714.51952303
Operating income: 1098047.696983867
Net income: 1184019.1723170446
Capital expenditures: 0
Depreciation & amortization: 150432.54617722702
Net tangible assets: 29005202.244563945
Owner earnings: 1334451.7184942716
Return on net tangible assets (%): 4.600732334987838
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 32000000
Book value: 29565489.829319615
Debt to equity: 0.0153121826849166
Current ratio: 1.9325214157241717
Quick ratio: 1.256403377739841
Effective tax rate (%): 25.483747553672064
Interest coverage ratio: 100.78004291845492
COGS to revenue (%): 51.19362443914658
Retained earnings: 9280722.46902034
Inventory turnover: 1.2228399320068355
Receivables turnover: 1.6545478962622426
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.4969255261006382
Rule of 40 score: 0
Financial ratios for BAJAJINDEF.NS — quarterly report dated 2025-06-30
Total revenue: 4646044.93330213
Gross profit: 2154551.8371167798
Operating income: 277837.5848350105
Net income: 661373.742101568
Capital expenditures: 0
Depreciation & amortization: 157278.25883454247
Owner earnings: 818652.0009361105
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 32000000
Effective tax rate (%): 25.33060307814255
Interest coverage ratio: 23.48565776458951
COGS to revenue (%): 53.62610848480423
Capitalized R&D asset: 0
Revenue growth (%): -24.98245784615973
Rule of 40 score: -24.98245784615973
Financial ratios for BAJAJINDEF.NS — quarterly report dated 2025-09-30
Total revenue: 5559131.905298759
Gross profit: 2576493.7993235625
Operating income: 545321.3077790304
Net income: 705693.3483652762
Capital expenditures: 0
Depreciation & amortization: 163055.2423900789
Net tangible assets: 27698297.632468995
Owner earnings: 868748.5907553551
Return on net tangible assets (%): 3.136469259890453
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 32000000
Book value: 28985016.910935737
Debt to equity: 0.015648173394410127
Current ratio: 1.383198984923123
Quick ratio: 0.6327237896203414
Effective tax rate (%): 16.137854842838472
Interest coverage ratio: 43.1875
COGS to revenue (%): 53.652947200843656
Inventory turnover: 0.8770545606439336
Receivables turnover: 3.1093419932528295
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.7778454072081946
Revenue growth (%): 19.652994861323098
Rule of 40 score: 19.652994861323098
Financial ratios for BAJAJINDEF.NS — quarterly report dated 2025-12-31
Total revenue: 5640848.835914003
Gross profit: 2568229.92090899
Operating income: 298507.29642419517
Net income: 545282.3883257213
Capital expenditures: 0
Depreciation & amortization: 157747.57714158404
Owner earnings: 703029.9654673053
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 32000000
Effective tax rate (%): 29.04621725051516
Interest coverage ratio: 32.83946078431372
COGS to revenue (%): 54.47086075844377
Capitalized R&D asset: 0
Revenue growth (%): 1.4699584756633304
Rule of 40 score: 1.4699584756633304
Financial ratios for BALPHARMA.NS — annual report dated 2022-03-31
Total revenue: 36884992.74693393
Gross profit: 14754134.247659238
Operating income: 1985981.8013978638
Net income: 752314.387445602
Capital expenditures: 1116879.8628511142
Operating cash flow: 3533627.8517737044
Depreciation & amortization: 1192153.5012528023
Net tangible assets: 6172622.972438349
Owner earnings: 827588.02584729
Return on net tangible assets (%): 13.407396329608817
Capex to operating income (%): 56.23817207514094
Buffett classification: The Good
Shares outstanding: 15920872
Book value: 7713622.576816563
Debt to equity: 1.8234232139560012
Current ratio: 1.114254183804251
Quick ratio: 0.6651266234295453
Effective tax rate (%): 37.87177504546791
Interest coverage ratio: 1.6968293672255272
COGS to revenue (%): 59.99962817158022
R&D to revenue (%): 0
SG&A to revenue (%): 6.26470107676505
Free cash flow (dilution-adjusted): 2416747.98892259
Retained earnings: 1791019.3854674932
Inventory turnover: 2.255755716735936
Receivables turnover: 3.7138541778700156
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.871026894865526
FCF margin (%): 6.552117294705127
Rule of 40 score: 6.552117294705127
Financial ratios for BALPHARMA.NS — annual report dated 2023-03-31
Total revenue: 36748757.61266748
Gross profit: 15281778.319123022
Operating income: 2137028.014616322
Net income: 319037.7588306943
Capital expenditures: 1783848.964677223
Operating cash flow: -187222.8989037759
Depreciation & amortization: 1111851.4007308162
Net tangible assets: 6029658.952496955
Owner earnings: -352959.8051157126
Return on net tangible assets (%): -5.8537275142161675
Capex to operating income (%): 83.47335423197492
Buffett classification: The Gruesome
Shares outstanding: 15920872
Book value: 7759098.660170522
Debt to equity: 2.0890832655701064
Current ratio: 1.0899111660577527
Quick ratio: 0.621736800067261
Effective tax rate (%): 44.83942297567653
Interest coverage ratio: 1.6715891768292683
COGS to revenue (%): 58.415523920037735
R&D to revenue (%): 0
SG&A to revenue (%): 6.031574310598385
Free cash flow (dilution-adjusted): -1971071.863580999
Retained earnings: 1789110.8404384898
Inventory turnover: 1.7983153920718333
Receivables turnover: 3.210475238864432
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 16.896528146274147
FCF margin (%): -5.363642179025831
Revenue growth (%): -0.3693511212030144
Rule of 40 score: -5.732993300228846
Financial ratios for BALPHARMA.NS — annual report dated 2024-03-31
Total revenue: 40678690.49046648
Gross profit: 15728384.698405085
Operating income: 2611212.3755846024
Net income: 892876.8437462526
Capital expenditures: 1315277.6112243675
Operating cash flow: 2734836.3113083104
Depreciation & amortization: 1207710.756685454
Net tangible assets: 6810912.579445977
Owner earnings: 785309.9892073392
Return on net tangible assets (%): 11.530172793250255
Capex to operating income (%): 50.37038057580059
Buffett classification: The Good
Shares outstanding: 15920872
Book value: 8630711.116440818
Debt to equity: 1.9764823575998838
Current ratio: 1.1531804831348014
Quick ratio: 0.7207333697106038
Effective tax rate (%): 17.702518983564158
Interest coverage ratio: 1.5035526124993959
COGS to revenue (%): 57.539717634240475
SG&A to revenue (%): 6.507259604103065
Free cash flow (dilution-adjusted): 1418131.6704640845
Retained earnings: 2644453.7714354238
Inventory turnover: 2.2227840317042755
Receivables turnover: 3.4050739898295355
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 18.645911024986066
FCF margin (%): 3.4861782750760866
Revenue growth (%): 10.694056433745496
Rule of 40 score: 14.180234708821583
Financial ratios for BALPHARMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 6382142.857142857
Buffett classification: The Gruesome
Shares outstanding: 15920872
Book value: 8212876.254180603
Debt to equity: 2.253588662879482
Current ratio: 1.1245910329688253
Quick ratio: 0.7174087087719775
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BALPHARMA.NS — quarterly report dated 2024-12-31
Total revenue: 8527147.686210513
Gross profit: 4231250.728523138
Operating income: 591304.3478260869
Net income: 60368.341298519634
Capital expenditures: 0
Depreciation & amortization: 313020.1655204569
Owner earnings: 373388.50681897654
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 15920872
Effective tax rate (%): 8.54670669256578
Interest coverage ratio: 1.0119491711384627
COGS to revenue (%): 50.37906127314283
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BALPHARMA.NS — annual report dated 2025-03-31
Total revenue: 35431762.91793313
Gross profit: 16973334.112695813
Operating income: 2313420.62193126
Net income: 846001.8704699555
Capital expenditures: 2196259.0600888473
Operating cash flow: 2374912.321720832
Depreciation & amortization: 1142260.9305588028
Net tangible assets: 7200315.641805003
Owner earnings: -207996.259060089
Return on net tangible assets (%): -2.888710292816381
Capex to operating income (%): 94.93557026630958
Buffett classification: The Gruesome
Shares outstanding: 15920872
Book value: 9048901.0989011
Debt to equity: 1.943215041024852
Current ratio: 1.0700304282044262
Quick ratio: 0.6006816391594909
Effective tax rate (%): -40.8603406326034
Interest coverage ratio: 1.1741147712170115
COGS to revenue (%): 52.095710981106514
SG&A to revenue (%): 7.9227723863373525
Free cash flow (dilution-adjusted): 178653.26163198502
Retained earnings: 3192705.167173252
Inventory turnover: 1.5326153003915661
Receivables turnover: 3.278578807595991
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.031600853430458
FCF margin (%): 0.5042178173459244
Revenue growth (%): -12.898467254650273
Rule of 40 score: -12.394249437304348
Financial ratios for BALPHARMA.NS — quarterly report dated 2025-03-31
Total revenue: 9571685.761047462
Gross profit: 4431049.801262567
Operating income: 638309.5627776479
Net income: 635164.8351648351
Capital expenditures: 0
Depreciation & amortization: 254886.60275894316
Net tangible assets: 7200315.641805003
Owner earnings: 890051.4379237783
Return on net tangible assets (%): 12.36128361868115
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 15920872
Book value: 9048924.47977554
Debt to equity: 1.9676814655478694
Current ratio: 1.0700304282044262
Quick ratio: 0.6006816391594909
Effective tax rate (%): -108.93421762936686
Interest coverage ratio: 1.3824437917763825
COGS to revenue (%): 53.706693764488335
Retained earnings: 3192705.167173252
Inventory turnover: 0.426830333656241
Receivables turnover: 0.8856890965833184
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.699285652810053
Revenue growth (%): 12.249560031968256
Rule of 40 score: 12.249560031968256
Financial ratios for BALPHARMA.NS — quarterly report dated 2025-06-30
Total revenue: 7707804.820968875
Gross profit: 3782857.4771823077
Operating income: 414193.77486543416
Net income: 24397.378890709104
Capital expenditures: 0
Depreciation & amortization: 294921.6007488884
Owner earnings: 319318.97963959747
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 15920872
Effective tax rate (%): 0
Interest coverage ratio: 0.8732668870577787
COGS to revenue (%): 50.92172719668321
Capitalized R&D asset: 0
Revenue growth (%): -19.47285970945432
Rule of 40 score: -19.47285970945432
Financial ratios for BALPHARMA.NS — quarterly report dated 2025-09-30
Total revenue: 8345535.5129650505
Gross profit: 3843246.8996617813
Operating income: 390011.27395715896
Net income: 80868.09470124013
Capital expenditures: 0
Depreciation & amortization: 256031.5670800451
Net tangible assets: 6993652.762119504
Owner earnings: 336899.6617812852
Return on net tangible assets (%): 4.817220317343637
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 15920872
Book value: 8830935.738444194
Debt to equity: 1.977254041853482
Current ratio: 1.0703937935294803
Quick ratio: 0.5780684378885489
Effective tax rate (%): 0
Interest coverage ratio: 0.8966822187662001
COGS to revenue (%): 53.94846869094047
Inventory turnover: 0.3543769012064785
Receivables turnover: 0.8150412613475588
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.871493327600418
Revenue growth (%): 8.273830316269123
Rule of 40 score: 8.273830316269123
Financial ratios for BALPHARMA.NS — quarterly report dated 2025-12-31
Total revenue: 9768263.339645762
Gross profit: 4626244.847944748
Operating income: 703486.6882031859
Net income: 199465.300211652
Capital expenditures: 0
Depreciation & amortization: 359797.25966358476
Owner earnings: 559262.5598752368
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 15920872
Effective tax rate (%): 0
Interest coverage ratio: 1.3020225553058573
COGS to revenue (%): 52.64004780493035
Capitalized R&D asset: 0
Revenue growth (%): 17.047771523714196
Rule of 40 score: 17.047771523714196
Financial ratios for BETA.NS — annual report dated 2023-03-31
Total revenue: 27663045.066991474
Gross profit: 11888928.136419002
Operating income: 5241254.567600488
Net income: 3741619.9756394643
Capital expenditures: 2218258.2216808773
Operating cash flow: 2848051.157125457
Depreciation & amortization: 1267965.8952496955
Net tangible assets: 14399744.214372717
Owner earnings: 2791327.6492082826
Return on net tangible assets (%): 19.38456411206384
Capex to operating income (%): 42.32303913252631
Buffett classification: The Good
Shares outstanding: 10094553
Book value: 14967624.84774665
Debt to equity: 0.16546065320033007
Current ratio: 2.02622988801239
Quick ratio: 1.5403414058991458
Effective tax rate (%): 25.179447834082303
Interest coverage ratio: 18.87311403508772
COGS to revenue (%): 57.022344764910606
SG&A to revenue (%): 2.6106318600031
Free cash flow (dilution-adjusted): 629792.9354445798
Retained earnings: 10880669.914738124
Inventory turnover: 4.22962111389445
Receivables turnover: 3.620915553699059
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 31.77911401005572
FCF margin (%): 2.276658024882702
Rule of 40 score: 2.276658024882702
Financial ratios for BETA.NS — annual report dated 2024-03-31
Total revenue: 35461537.281208776
Gross profit: 13732575.701403046
Operating income: 6012033.2240076745
Net income: 4369470.099412399
Capital expenditures: 1392947.8096894112
Operating cash flow: 3709113.7336611105
Depreciation & amortization: 1173074.349682216
Net tangible assets: 18195112.943398487
Owner earnings: 4149596.639405205
Return on net tangible assets (%): 22.80610542135026
Capex to operating income (%): 23.169329872080446
Buffett classification: The Great
Shares outstanding: 10094553
Book value: 18841217.3430867
Debt to equity: 0.09362974158969424
Current ratio: 2.1007470133002495
Quick ratio: 1.5124292233948733
Effective tax rate (%): 25.264004133325237
Interest coverage ratio: 18.723995315473413
COGS to revenue (%): 61.27473100643046
SG&A to revenue (%): 2.652137332815044
Free cash flow (dilution-adjusted): 2316165.923971699
Retained earnings: 14817486.092577048
Inventory turnover: 3.6376178310323453
Receivables turnover: 3.731880791177571
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 29.590055014132037
FCF margin (%): 6.531487638577489
Revenue growth (%): 28.19101149324569
Rule of 40 score: 34.72249913182318
Financial ratios for BETA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 20972055.054108936
Buffett classification: The Gruesome
Shares outstanding: 10094553
Book value: 21603021.39811276
Debt to equity: 0.10538272120022399
Current ratio: 2.1462489896080448
Quick ratio: 1.5864678451236747
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BETA.NS — quarterly report dated 2024-12-31
Total revenue: 10291251.023545867
Gross profit: 5362310.502739246
Operating income: 1773526.4659051169
Net income: 1042983.1319501107
Capital expenditures: 0
Depreciation & amortization: 377362.706958853
Owner earnings: 1420345.8389089636
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 10094553
Effective tax rate (%): 25.182414539429697
Interest coverage ratio: 8.10679402406551
COGS to revenue (%): 47.89447375765542
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BETA.NS — annual report dated 2025-03-31
Total revenue: 42360967.86006546
Gross profit: 22329019.691606265
Operating income: 7258711.928571428
Net income: 4958914.042787001
Capital expenditures: 4308921.727262099
Operating cash flow: 4228735.749707739
Depreciation & amortization: 1462945.0642974046
Net tangible assets: 22039135.846972175
Owner earnings: 2112937.3798223054
Return on net tangible assets (%): 9.587206115944829
Capex to operating income (%): 59.362070979859496
Buffett classification: The Good
Shares outstanding: 10094553
Book value: 23041356.899462238
Debt to equity: 0.7004483524166035
Current ratio: 3.222799724744668
Quick ratio: 2.640956027702094
Effective tax rate (%): 25.540864891388072
Interest coverage ratio: 8.883968149324946
COGS to revenue (%): 47.2886932957538
SG&A to revenue (%): 3.8276832484957244
Free cash flow (dilution-adjusted): -80185.97755436052
Retained earnings: 19117406.852934297
Inventory turnover: 2.866753618112501
Receivables turnover: 3.532477085147432
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 18.617717173131854
FCF margin (%): -0.18929212811955948
Revenue growth (%): 19.456095555430764
Rule of 40 score: 19.266803427311203
Financial ratios for BETA.NS — quarterly report dated 2025-03-31
Total revenue: 10961383.454874912
Gross profit: 5821963.920037409
Operating income: 1610770.8369184004
Net income: 1056161.1896188916
Capital expenditures: 0
Depreciation & amortization: 417039.9960252513
Net tangible assets: 22039135.846972175
Owner earnings: 1473201.1856441428
Return on net tangible assets (%): 6.684477993480571
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 10094553
Book value: 23041356.899462238
Debt to equity: 0.7004483524166035
Current ratio: 3.222799724744668
Quick ratio: 2.640956027702094
Effective tax rate (%): 26.14804002300959
Interest coverage ratio: 4.1940931949078175
COGS to revenue (%): 46.88659561993356
Retained earnings: 19117406.852934297
Inventory turnover: 0.73549758728368
Receivables turnover: 0.9140687248641155
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.131432155949701
Revenue growth (%): 6.511671222437545
Rule of 40 score: 6.511671222437545
Financial ratios for BETA.NS — quarterly report dated 2025-09-30
Capital expenditures: 0
Net tangible assets: 23875602.57643743
Buffett classification: The Gruesome
Shares outstanding: 10094553
Book value: 24916830.18060879
Debt to equity: 0.659497942858825
Current ratio: 3.0929742730173544
Quick ratio: 2.4545421467161255
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for BETA.NS — quarterly report dated 2025-12-31
Total revenue: 9721235.877130445
Gross profit: 5706134.444580595
Operating income: 1403216.2710259554
Net income: 948786.5352567673
Capital expenditures: 0
Depreciation & amortization: 488952.87902417296
Owner earnings: 1437739.4142809403
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 10094553
Effective tax rate (%): 18.666670857382496
Interest coverage ratio: 2.8407327517905645
COGS to revenue (%): 41.302376398411646
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FHP.L — annual report dated 2021-08-31
Total revenue: 0
Operating income: -250684.93150684933
Net income: -678082.1917808219
Capital expenditures: 0
Operating cash flow: 72602.7397260274
Net tangible assets: -535616.4383561644
Owner earnings: -678082.1917808219
Buffett classification: The Gruesome
Shares outstanding: 134002000
Book value: -535616.4383561644
Debt to equity: -0.1278772378516624
Current ratio: 0.5251700680272109
Quick ratio: 0.5251700680272109
Free cash flow (dilution-adjusted): 72602.7397260274
Retained earnings: -1512328.7671232878
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FHP.L — annual report dated 2024-02-29
Total revenue: 0
Operating income: -464556.96202531643
Net income: -964556.9620253164
Capital expenditures: 0
Operating cash flow: -434177.2151898734
Net tangible assets: -788607.5949367088
Owner earnings: -964556.9620253164
Buffett classification: The Gruesome
Shares outstanding: 134002000
Book value: -788607.5949367088
Debt to equity: -0.051364365971107544
Current ratio: 0.044515103338632754
Quick ratio: 0.044515103338632754
Interest coverage ratio: -367
Free cash flow (dilution-adjusted): -434177.2151898734
Retained earnings: -2541772.1518987343
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for NIBEB.SW — annual report dated 2022-12-31
Total revenue: 43555434782.608696
Gross profit: 13705434782.608696
Operating income: 5675000000
Net income: 4777173913.043478
Capital expenditures: 2133695652.173913
Operating cash flow: 2841304347.826087
Depreciation & amortization: 1735869565.2173913
Net tangible assets: 5833695652.173913
Owner earnings: 4379347826.086956
Return on net tangible assets (%): 75.06987143655672
Capex to operating income (%): 37.59816127178701
Buffett classification: The Good
Shares outstanding: 1782940032
Book value: 30405434782.608696
Debt to equity: 0.3983484073928431
Current ratio: 1.6107031193194212
Quick ratio: 0.8697011561113939
Effective tax rate (%): 22.555066079295155
Interest coverage ratio: 20.080769230769235
COGS to revenue (%): 68.53335329789624
SG&A to revenue (%): 18.888972074567643
Free cash flow (dilution-adjusted): 405434782.6086956
Retained earnings: 20963043478.260868
Inventory turnover: 2.694730644686488
Receivables turnover: 6.89334250817134
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.97432966377575
FCF margin (%): 0.9308477452521773
Rule of 40 score: 0.9308477452521773
Financial ratios for NIBEB.SW — annual report dated 2023-12-31
Total revenue: 55534523809.52381
Gross profit: 18598809523.809525
Operating income: 7652380952.380953
Net income: 5709523809.523809
Capital expenditures: 3823809523.809524
Operating cash flow: 3071428571.4285717
Depreciation & amortization: 2171428571.4285717
Net tangible assets: -1016666666.6666667
Owner earnings: 4057142857.142857
Return on net tangible assets (%): -399.06323185011706
Capex to operating income (%): 49.96888612321095
Buffett classification: The Good
Shares outstanding: 1782940032
Book value: 35960714285.71429
Debt to equity: 0.6938789022412024
Current ratio: 1.5546418246064888
Quick ratio: 0.7048506264053966
Effective tax rate (%): 24.24577475912178
Interest coverage ratio: 7.287981859410431
COGS to revenue (%): 66.50946429719824
SG&A to revenue (%): 20.309117022872943
Free cash flow (dilution-adjusted): -1357142857.142857
Retained earnings: 27014285714.285717
Inventory turnover: 2.3456566114765254
Receivables turnover: 9.32047952047952
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.234720874017396
FCF margin (%): -2.4437822890094103
Revenue growth (%): 27.50308678286518
Rule of 40 score: 25.05930449385577
Financial ratios for NIBEB.SW — annual report dated 2024-12-31
Total revenue: 45023333333.333336
Gross profit: 12193333333.333334
Operating income: 2020000000
Net income: 1303333333.3333333
Capital expenditures: 2395555555.5555553
Operating cash flow: 4451111111.111111
Depreciation & amortization: 2494444444.444444
Net tangible assets: -158888888.8888889
Owner earnings: 1402222222.2222223
Return on net tangible assets (%): -882.5174825174824
Capex to operating income (%): 118.5918591859186
Buffett classification: The Gruesome
Shares outstanding: 1782940032
Book value: 35711111111.11111
Debt to equity: 0.7385812072184195
Current ratio: 1.4968372627947095
Quick ratio: 0.8167529231359019
Effective tax rate (%): 24.348958333333336
Interest coverage ratio: 1.281183932346723
COGS to revenue (%): 72.9177463537425
SG&A to revenue (%): 23.326176550430638
Free cash flow (dilution-adjusted): 1510000000
Retained earnings: 25015555555.555553
Inventory turnover: 2.7759301014656144
Receivables turnover: 7.470685840707965
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.3202447265089945
FCF margin (%): 3.3538165395720734
Revenue growth (%): -18.92730819524534
Rule of 40 score: -15.57349165567327
Financial ratios for NIBEB.SW — quarterly report dated 2025-03-31
Total revenue: 10992045454.545454
Gross profit: 3260227272.7272725
Operating income: 888636363.6363636
Net income: 445454545.45454544
Capital expenditures: 0
Operating cash flow: 276136363.6363636
Net tangible assets: -171590909.0909091
Owner earnings: 445454545.45454544
Return on net tangible assets (%): -259.6026490066225
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1782940032
Book value: 34029545454.545464
Debt to equity: 0.7880852200627795
Current ratio: 1.5032137673647108
Quick ratio: 0.8213421798327459
Effective tax rate (%): 23.929961089494164
COGS to revenue (%): 70.34012198904168
SG&A to revenue (%): 22.867776284503254
Free cash flow (dilution-adjusted): 276136363.6363636
Inventory turnover: 0.6896411919724306
Receivables turnover: 1.335127674258109
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.5180339325231975
FCF margin (%): 2.512147213894345
Rule of 40 score: 2.512147213894345
Financial ratios for NIBEB.SW — quarterly report dated 2025-06-30
Total revenue: 12602500000
Gross profit: 3811250000
Operating income: 1180000000
Net income: 617500000
Capital expenditures: 0
Operating cash flow: 457500000
Net tangible assets: -307500000
Owner earnings: 617500000
Return on net tangible assets (%): -200.81300813008133
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1782940032
Book value: 37328750000
Debt to equity: 0.8642132404647892
Current ratio: 1.4196011879507848
Quick ratio: 0.8176859203588096
Effective tax rate (%): 29.428571428571427
COGS to revenue (%): 69.7579845268796
SG&A to revenue (%): 22.059115254909738
Free cash flow (dilution-adjusted): 457500000
Inventory turnover: 0.7081864867586346
Receivables turnover: 1.2813929842399594
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.837111997664688
FCF margin (%): 3.630232096806189
Revenue growth (%): 14.651090664736902
Rule of 40 score: 18.28132276154309
Financial ratios for NIBEB.SW — quarterly report dated 2025-09-30
Total revenue: 12607500000
Gross profit: 4068750000
Operating income: 1423750000
Net income: 762500000
Capital expenditures: 0
Operating cash flow: 2880000000
Net tangible assets: 416250000
Owner earnings: 762500000
Return on net tangible assets (%): 183.1831831831832
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1782940032
Book value: 37692500000
Debt to equity: 0.7929627910061683
Current ratio: 1.5135790821483928
Quick ratio: 0.8557854302850596
Effective tax rate (%): 32.671081677704194
COGS to revenue (%): 67.72754312908982
SG&A to revenue (%): 21.83224271267103
Free cash flow (dilution-adjusted): 2880000000
Inventory turnover: 0.6998258375166478
Receivables turnover: 1.2615384615384615
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.206423617837356
FCF margin (%): 22.843545508625816
Revenue growth (%): 0.0396746677246578
Rule of 40 score: 22.883220176350473